New cancer vaccine approaches

被引：4

作者：

Kaplan, JM ^{[1
]}

机构：

[1] Genzyme Corp, Framingham, MA 01701 USA

来源：

DRUGS OF TODAY | 2004年 / 40卷 / 11期

关键词：

D O I：

10.1358/dot.2004.40.11.872580

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The use of tumor vaccines as a therapeutic modality for the treatment of cancer is a very exciting and promisino area of research. Unlike chemotherapy, vaccination against tumor antigens has the potential to specifically target cancer cells without damage to normal tissues or debilitating side effects. Recent progress in immunology and tumor biology has allowed for the development of new vaccination strategies and approaches to enhance clinical efficacy. (C) 2004 Prous Science. All rights reserved.

引用

收藏

页码：913 / 929

页数：17

相关论文

共 130 条

[1]

Aarts WM, 2002, CANCER RES, V62, P5770

[2] A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L [J].

Ahlers, JD ;

Belyakov, IM ;

Terabe, M ;

Koka, R ;

Donaldson, DD ;

Thomas, EK ;

Berzofsky, JA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) :13020-13025

[3] Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].

Albert, ML ;

Sauter, B ;

Bhardwaj, N .

NATURE, 1998, 392 (6671) :86-89

[4] Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen [J].

Allen, TM ;

Vogel, TU ;

Fuller, DH ;

Mothé, BR ;

Steffen, S ;

Boyson, JE ;

Shipley, T ;

Fuller, J ;

Hanke, T ;

Sette, A ;

Altman, JD ;

Moss, B ;

McMichael, AJ ;

Watkins, DI .

JOURNAL OF IMMUNOLOGY, 2000, 164 (09) :4968-4978

[5]

Armstrong Todd D, 2002, Surg Oncol Clin N Am, V11, P681, DOI 10.1016/S1055-3207(02)00020-0

[6]

ASSIKIS VJ, 2003, M AM SOC CLIN ONC 20

[7] CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin [J].

Basu, S ;

Binder, RJ ;

Ramalingam, T ;

Srivastava, PK .

IMMUNITY, 2001, 14 (03) :303-313

[8]

BERD D, 2002, CLIN EXP DERMATOL, V27, P597

[9] Efficacy and safety of HLA-B7/β-2 microglobulin plasmid DNA/lipid complex (Allovectin-7®) in patients with metastatic melanoma [J].

Bergen, M ;

Chen, R ;

Gonzalez, R .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2003, 3 (02) :377-384

[10] Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes [J].

Blake, J ;

Johnston, JV ;

Hellstrom, KE ;

Marquardt, H ;

Chen, LP .

JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (01) :121-130

← 1 2 3 4 5 6 7 8 9 10 →